Dr. Bevilacqua was an invited speaker and panelist at FDA sponsored Duke-Margolis meeting on the topic of developing “… Emerging Non-traditional Antibiotics”.
WASHINGTON, DC - June 14, 2018 - Dr. Michael Bevilacqua, Amicrobe’s founder and CEO, was an invited speaker and panelist at an FDA sponsored meeting on the topic of developing “… Emerging Non-traditional Antibiotics”. This one day event was convened by the Duke-Robert J. Margolis, MD, Center for Health Policy.
Dr. Bevilacqua delivered a talk entitled, "Purpose-built antimicrobials for surgery and trauma". He discussed the progression of infection from initial wound contamination through local infection and on to systemic invasion / sepsis. Further, he described how Amicrobe's two lead product programs, the Amicidin-Alpha Surgical Gel and the Amicidin-Beta Solution, are purpose-built to go into the wounds of surgery and trauma in order to interrupt this life-threatening progression.
A video of the 10 minute presentation can be found here.